Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sino Biopharm to Partner China Development of Boehringer Ingelheim Portfolio

publication date: Apr 9, 2024

Sino Biopharm announced a strategic partnership with Germany’s Boehringer Ingelheim to develop and commercialize Boehringer 's innovative oncology pipeline in mainland China. The agreement includes three clinical stage assets and an unspecified number of preclinical projects, all of them aimed at oncology targets. Sino Biopharm actively seeks in-licensing deals from other companies. Last year, it signed a commercialization deal with Shanghai’s Investisbio for a KRAS G12C inhibitor and another agreement for a portfolio of 12 innovative Pfizer drugs. More details....

Stock Symbol: (HK: 01177)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital